{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:18:54Z","timestamp":1791497934003,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009337","name":"Saitama Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis of pooled data was conducted, and the risk ratio with corresponding confidence intervals was calculated in the meta-analysis and summarized. Sixteen studies were included in the qualitative analysis, nine of which were examined in the meta-analysis. Although G-CSF significantly shortened the duration of neutropenia, primary prophylaxis with G-CSF did not correlate with infection-related mortality. Moreover, primary prophylaxis with G-CSF did not affect disease progression\/recurrence, overall survival, or adverse events, such as musculoskeletal pain. However, evidence to support or discourage the use of G-CSF as primary prophylaxis for adult AML patients with induction therapy remains limited. Therefore, the use of G-CSF as primary prophylaxis can be considered for adult AML patients with remission induction therapy who are at a high risk of infectious complications.<\/jats:p>","DOI":"10.1007\/s10147-023-02465-0","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T03:01:45Z","timestamp":1710730905000},"page":"535-544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology"],"prefix":"10.1007","volume":"29","author":[{"given":"Tomoya","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miumra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Susumu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munetaka","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"2465_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348","journal-title":"CA Cancer J Clin"},{"key":"2465_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/14787210.2020.1820863","volume":"19","author":"AM Peseski","year":"2021","unstructured":"Peseski AM, McClean M, Green SD et al (2021) Management of fever and neutropenia in the adult patient with acute myeloid leukemia. Expert Rev Anti Infect Ther 19:359\u2013378","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2465_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1056\/NEJM199009273231304","volume":"323","author":"R Ohno","year":"1990","unstructured":"Ohno R, Tomonaga M, Kobayashi T et al (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871\u2013877","journal-title":"N Engl J Med"},{"key":"2465_CR4","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.bbmt.2011.07.003","volume":"17","author":"BR Avalos","year":"2011","unstructured":"Avalos BR, Lazaryan A, Copelan EA (2011) Can G-CSF cause leukemia in hematopoietic stem cell donors? Biol Blood Marrow Transplant 17:1739\u20131746","journal-title":"Biol Blood Marrow Transplant"},{"key":"2465_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/09511920410001713574","volume":"13","author":"LL De Figueiredo","year":"2004","unstructured":"De Figueiredo LL, De Abreu e Lima RS, Rego EM (2004) Granulocyte colony-stimulating factor and leukemogenesis. Mediators Inflamm 13:145\u2013150","journal-title":"Mediators Inflamm"},{"key":"2465_CR6","unstructured":"Morizane T, Yoshida M, Kojimahara N et al (2014) Minds handbook for clinical practice guideline development 2014. Japan Council for Quality Health Care, Tokyo. https:\/\/minds.jcqhc.or.jp\/s\/developer_manual (in Japanese)"},{"key":"2465_CR7","unstructured":"Kojimahara N, Nakayama T, Morizane T et al (2017) Minds manual for guideline development 2017. Japan Council for Quality Health Care, Tokyo. https:\/\/minds.jcqhc.or.jp\/s\/developer_manual (in Japanese)"},{"key":"2465_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/sj.leu.2402218","volume":"15","author":"K Bradstock","year":"2001","unstructured":"Bradstock K, Matthews J, Young G et al (2001) Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia 15:1331\u20131338","journal-title":"Leukemia"},{"key":"2465_CR9","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1182\/blood.V90.12.4710","volume":"90","author":"G Heil","year":"1997","unstructured":"Heil G, Hoelzer D, Sanz MA et al (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 90:4710\u20134708","journal-title":"Blood"},{"key":"2465_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.1365-2141.2002.03251.x","volume":"116","author":"K Usuki","year":"2002","unstructured":"Usuki K, Urabe A, Masaoka T et al (2002) Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 116:103\u2013112","journal-title":"Br J Haematol"},{"key":"2465_CR11","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1182\/blood.V91.10.3607","volume":"91","author":"JE Godwin","year":"1998","unstructured":"Godwin JE, Kopecky KJ, Head DR et al (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood. 91:3607\u20133615","journal-title":"Blood."},{"key":"2465_CR12","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1056\/NEJM199506223322504","volume":"332","author":"H Dombret","year":"1995","unstructured":"Dombret H, Chastang C, Fenaux P et al (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 332:1678\u20131683","journal-title":"N Engl J Med"},{"key":"2465_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1081\/CNV-100104288","volume":"19","author":"CL Bennett","year":"2001","unstructured":"Bennett CL, Hynes D, Godwin J et al (2001) Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. Cancer Invest 19:603\u2013610","journal-title":"Cancer Invest"},{"key":"2465_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1365-2141.2009.07710.x","volume":"146","author":"K Wheatley","year":"2009","unstructured":"Wheatley K, Goldstone AH, Littlewood T et al (2009) Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol 146:54\u201363","journal-title":"Br J Haematol"},{"key":"2465_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.leukres.2010.07.005","volume":"35","author":"M Beksac","year":"2011","unstructured":"Beksac M, Ali R, Ozcelik T et al (2011) Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial. Leuk Res 35:340\u2013345","journal-title":"Leuk Res"},{"key":"2465_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1182\/blood-2004-09-3728","volume":"106","author":"S Amadori","year":"2005","unstructured":"Amadori S, Suciu S, Jehn U et al (2005) Use of glycosylated recombinant human G-CSF (lenograstim) during and\/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 106:27\u201334","journal-title":"Blood"},{"key":"2465_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2017.02.003","volume":"57","author":"KW Kang","year":"2017","unstructured":"Kang KW, Kim DS, Lee SR et al (2017) Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies. Leuk Res 57:1\u20138","journal-title":"Leuk Res"},{"key":"2465_CR18","first-page":"420","volume":"57","author":"M Kawato","year":"2003","unstructured":"Kawato M, Mikuni C, Hirota Y et al (2003) Effect of Granulocyte colony-stimulating factor on neutropenia after chemotherapy in acute myeloid leukemia. Iryo 57:420\u2013425 ((in Japanese))","journal-title":"Iryo"},{"key":"2465_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00019053-200220100-00003","volume":"20","author":"B Standaert","year":"2002","unstructured":"Standaert B, Goldstone J, Lu ZJ et al (2002) Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data. Pharmacoeconomics 20:665\u2013674","journal-title":"Pharmacoeconomics"},{"key":"2465_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/10428199509059638","volume":"18","author":"JL Harousseau","year":"1995","unstructured":"Harousseau JL, Wu D (1995) The use of GM-CSF and G-CSF in the treatment of acute leukemias. Leuk Lymphoma 18:405\u2013412","journal-title":"Leuk Lymphoma"},{"key":"2465_CR21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/phar.1150","volume":"32","author":"AM Bradley","year":"2012","unstructured":"Bradley AM, Deal AM, Buie LW et al (2012) Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor. Pharmacotherapy 32:1070\u20131077","journal-title":"Pharmacotherapy"},{"key":"2465_CR22","first-page":"32","volume":"10","author":"PG Maslak","year":"1996","unstructured":"Maslak PG, Weiss MA, Berman E et al (1996) Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Leukemia 10:32\u201339","journal-title":"Leukemia"},{"key":"2465_CR23","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719","journal-title":"Leukemia"},{"key":"2465_CR24","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228","journal-title":"Blood"},{"key":"2465_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.V41.4.489.489","volume":"41","author":"J Bernard","year":"1973","unstructured":"Bernard J, Weil M, Boiron M et al (1973) Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 41:489\u2013496","journal-title":"Blood"},{"key":"2465_CR26","unstructured":"National Comprehensive Cancer Network (2023) Hematopoietic growth factors. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf. (Version 2; 2023). Accessed Oct 2023"},{"key":"2465_CR27","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212","journal-title":"J Clin Oncol"},{"key":"2465_CR28","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/cncr.25691","volume":"117","author":"GH Lyman","year":"2011","unstructured":"Lyman GH, Kuderer NM, Crawford J et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917\u20131927","journal-title":"Cancer"},{"key":"2465_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/10428199709042494","volume":"25","author":"K Shinjo","year":"1997","unstructured":"Shinjo K, Takeshita A, Ohnishi K et al (1997) Granulocyte colony-stimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells. Leuk Lymphoma 25:37\u201346","journal-title":"Leuk Lymphoma"},{"key":"2465_CR30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/16078454.2021.1965725","volume":"26","author":"A Theyab","year":"2021","unstructured":"Theyab A, Algahtani M, Alsharif KF et al (2021) New insight into the mechanism of granulocyte colony-stimulating factor (G-CSF) that induces the mobilization of neutrophils. Hematology 26:628\u2013636","journal-title":"Hematology"},{"key":"2465_CR31","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/leu.2013.321","volume":"28","author":"HM Mehta","year":"2014","unstructured":"Mehta HM, Futami M, Glaubach T et al (2014) Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition. Leukemia 28:1041\u20131051","journal-title":"Leukemia"},{"key":"2465_CR32","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2009.25.9010","volume":"28","author":"S Ehlers","year":"2010","unstructured":"Ehlers S, Herbst C, Zimmermann M et al (2010) Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol 28:2591\u20132597","journal-title":"J Clin Oncol"},{"key":"2465_CR33","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670\u20132677","journal-title":"J Clin Oncol"},{"key":"2465_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629","journal-title":"N Engl J Med"},{"key":"2465_CR35","doi-asserted-by":"publisher","first-page":"E416","DOI":"10.1002\/ajh.26692","volume":"97","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, DiNardo CD, Selleslag D et al (2022) Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol 97:E416\u2013E419","journal-title":"Am J Hematol"},{"key":"2465_CR36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1524-4733.2008.00434.x","volume":"12","author":"SD Ramsey","year":"2009","unstructured":"Ramsey SD, Liu Z, Boer R et al (2009) Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 12:217\u2013225","journal-title":"Value Health"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02465-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02465-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02465-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T03:43:06Z","timestamp":1714016586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02465-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2465"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02465-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"7 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TMa received research funding from Chugai. SN received honoraria from Kyowa Kirin. YO received honoraria from Daiichi Sankyo, Pfizer, Chugai, Eli Lilly, and Kyowa Kirin. KT received honoraria from Ono, Chugai, Taiho, and Novartis. EI received honoraria from Eli Lilly and research funding from MSD, Ono, Janssen, and Takeda. YM received honoraria from Ono, MSD, Takeda, Eisai, and Bristol Myers Squibb and research funding from MSD, Ono. DM received honoraria from Ono, Janssen, Nippon Shinyaku, Eisai, Mundi pharma, Kyowa Kirin, Chugai, Zenyaku, MSD, SymBio, Sanofi, AbbVie, Takeda, AstraZeneca, Bristol Myers Squibb, and Genmab and research funding from Amgen, Astellas, BioPharma, Novartis, Kyowa Kirin, Ono, Chugai, Janssen, Takeda, Otsuka, Sanofi, Bristol Myers Squibb, AbbVie, Eisai, MSD, Taiho, AstraZeneca, Eli Lilly, and Genmab. TY received honoraria from Kyowa Kirin, Pfizer, Chugai, Eli Lilly, MSD, AstraZeneca, and Eisai. TMo received honoraria from AstraZeneca, Chugai, and Myriad Genetics. EB received honoraria from Chugai, and Daiichi Sankyo and research funding from Taiho, and Chugai. TKu received honoraria from Chugai. TKi received honoraria from Sanofi. AS received honoraria from Chugai, and Taiho and scholarship donations Chugai, and Taiho. TT received honoraria from Daiichi Sankyo, Chugai, and Eli Lilly. SY received research funding from Otsuka. No other author has reported a potential conflict of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not Applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors consented to the publication of this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}